648904-46-5

Upstream product

• 648904-49-8 6-methoxy-1-[4-(2-piperidin-1-ylethoxy)phenoxy]naphthalene-2-ol 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 194594-62-2 1-bromo-6-methoxynaphthalen-2-ol 
• 5111-66-0 6-Methoxy-2-naphthol 
• 100238-42-4 4-(2-piperidin-1-yl-ethoxy)-phenol 
• 648904-48-7 1-{2-[4-(2-benzyloxy-6-methoxynaphthalen-1-yloxy)phenoxy]ethyl}piperidine 
• 648904-47-6 2-(benzyloxy)-1-bromo-6-methoxynaphthalene 

Downstream Products

• 648905-66-2 4-{6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl}-N,N-dimethylbenzenesulfonamide 
• 648904-77-2 1-(2-{4-[2-(4-ethanesulfonyl-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine 
• 946077-38-9 C₃₃H₃₇NO₅S 
• 862155-77-9 C₃₁H₃₀N₂O₃ 
• 203872-36-0 C₃₀H₃₁NO₄ 
• 946077-39-0 C₃₀H₃₁NO₄ 
• 862081-57-0 4-{6-methoxy-1-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-yl}-N,N-dimethyl-benzamide 
• 861930-34-9 1-(2-{4-[2-(3-fluoro-phenyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine 
• 946077-40-3 C₃₀H₂₉NO₃F₂ 
• 862129-83-7 1-(2-{4-[2-(3,6-dihydro-2H-thiopyran-4-yl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine 
• 862129-75-7 (+/-)-1-(2-{4-[2-(4-methanesulfonyl-cyclohex-1-enyl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine 
• 861930-46-3 6-(4-fluorophenyl)-5-[4-(2-piperidin-1-ylethoxy)phenoxy]naphthalen-2-ol 
• 862130-05-0 6-(4-methanesulfonyl-cyclohexyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenoxy]-naphthalen-2-ol 
• 862129-82-6 1-(2-{4-[2-(1,1-dioxo-1,2,3,6-tetrahydro-1λ6-thiopyran-4-yl)-6-methoxy-naphthalen-1-yloxy]-phenoxy}-ethyl)-piperidine 

Relevant academic research and scientific papers

SELECTIVE ESTROGEN RECEPTOR MODULATOR

The present invention is directed to a compound of the formula (A): or a pharmaceutically acceptable salt thereof; and also to compounds of formula (I): or a pharmaceutically acceptable salt thereof.

Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety

Structure-activity relationship studies are described, which led to the discovery of novel selective estrogen receptor modulators (SERMs) for the potential treatment of uterine fibroids. The SAR studies focused on limiting brain exposure and were guided by computational properties. Compounds with limited impact on the HPO axis were selected using serum estrogen levels as a biomarker for ovarian stimulation.

A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats

The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. 16 (LY2066948-HCl) binds with high affinity to estrogen receptors α and β (ERα and ERβ, respectively) and is a potent uterine

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The present invention relates to a selective estrogen receptor modulator of formula I: or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and uterine leiomyoma.

SELECTIVE ESTROGEN RECEPTOR MODULATORS

The present invention relates to a selective estrogen receptor modulators of formula I (I); or a pharmaceutical acid addition salt thereof; and of formula II (II); or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

SELECTIVE ESTROGEN RECEPTOR MODULATORS FOR THE TREATMENT OF VASOMOTOR SYMPTOMS

The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.

SELECTIVE ESTROGEN RECEPTOR MODULATORS CONTAINING A PHENYLSULFONYL GROUP

The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.